Program
sintilimab
Also written as “Sintilimab”, “IBI308” and “IBI939+ Sintilimab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Stomach Neoplasms · Colorectal Neoplasms · Esophageal Squamous Cell Carcinoma, led by 10 companies.
Drug pageSintilimab: every studyMany companies study it; this page follows only the 40 they lead. All 403 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologicsits history only | 295 open or running | phase 3since May 7, 2017 | Oct 8, 2016 | Mar 25, 2030phase 3 · NCT07917468 |
| HUTCHMEDits history only | 31 open or running | phase 3since Aug 16, 2022 | Mar 27, 2019 | Jan 8, 2029phase 3 · NCT06584032 |
| Beijing Aosaikang Pharmaceuticalits history only | 11 open or running | phase 2since Nov 21, 2022 | Nov 21, 2022 | none ahead |
| Chipscreen Biosciencesits history only | 11 open or running | phase 3since Jun 28, 2024 | Jun 28, 2024 | May 31, 2028phase 3 · NCT06497985 |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 2since Jul 30, 2026 | Jul 30, 2026 | Sep 30, 2029phase 2 · NCT07761286 |
| Sichuan Luzhou Buchang Biopharmaceuticalits history only | 11 open or running | phase 1since Jan 2, 2025 | Jan 2, 2025 | none ahead |
| Simcere Pharmaceutical Groupits history only | 10 open or running | phase 1since Jan 29, 2023 | Jan 29, 2023 | none ahead |
| Suzhou Zelgen Biopharmaceuticalsits history only | 11 open or running | phase 2since Aug 14, 2024 | Aug 14, 2024 | none ahead |
| TaiRxits history only | 11 open or running | phase 2since Mar 31, 2026 | Mar 31, 2026 | Dec 31, 2027phase 2 · NCT07521852 |
| TJ Biopharmaits history only | 11 open or running | phase 2since May 21, 2025 | May 21, 2025 | none ahead |
Also a collaborator on its studies: Fortrea.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 26 earlier studies, Oct 8, 2016 to Aug 16, 2022.
- Jun 9, 2018Named sintilimabINNProposed as its International Nonproprietary Name in WHO's List 119 · before, IBI308
- Oct 5, 2022Phase 2 study in MelanomaInnovent Biologics · NCT05572463 · United States, Australia, France and more
- Nov 21, 2022Beijing Aosaikang Pharmaceutical’s first study: phase 2 study in Stomach NeoplasmsNew to Beijing Aosaikang PharmaceuticalBeijing Aosaikang Pharmaceutical · NCT05632939 · 62 enrolled · China
- Jan 29, 2023Simcere Pharmaceutical Group’s first study: phase 1 study in Advanced Solid TumorsNew to Simcere Pharmaceutical GroupSimcere Pharmaceutical Group · NCT05718219 · 49 enrolled · China
- Apr 17, 2023Phase 2 study in Non-squamous Non-small-cell Lung CancerInnovent Biologics · NCT05849246 · 4 enrolled · China
- Jun 28, 2024Chipscreen Biosciences’ first study: phase 3 study in Colorectal NeoplasmsNew to Chipscreen BiosciencesChipscreen Biosciences · NCT06497985 · 430 planned · China
- Aug 14, 2024Suzhou Zelgen Biopharmaceuticals’ first study: phase 2 study in Carcinoma, HepatocellularNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT06558227 · 90 planned · China
- Aug 21, 2024Phase 3 study in Endometrial NeoplasmsHUTCHMED · NCT06584032 · 412 planned · China
- Jan 2, 2025Sichuan Luzhou Buchang Biopharmaceutical’s first study: phase 1 study in Stomach NeoplasmsNew to Sichuan Luzhou Buchang BiopharmaceuticalSichuan Luzhou Buchang Biopharmaceutical · NCT06773312 · 80 planned · China
- May 21, 2025TJ Biopharma’s first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to TJ BiopharmaTJ Biopharma · NCT07005336 · 150 enrolled · China
- Mar 16, 2026Phase 2 study in CLDN18.2 PositiveInnovent Biologics · NCT07483567 · 90 planned · China
- Mar 31, 2026TaiRx’s first study: phase 2 study in Carcinoma, HepatocellularNew to TaiRxTaiRx · NCT07521852 · 40 planned · China
- Jun 4, 2026Phase 3 study in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaInnovent Biologics · NCT07643623 · 720 planned · China
- Jul 30, 2026CSPC Pharmaceutical Group’s first study: phase 2 study in Carcinoma, HepatocellularNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT07761286 · 288 planned · China
- Oct 19, 2026Phase 3 study in Locally Advanced Rectal CancerInnovent Biologics · NCT07917468 · 500 planned · China
Ahead
- Dec 31, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularTaiRx · NCT07521852
- May 31, 2028Primary completion: phase 3 study in Colorectal NeoplasmsChipscreen Biosciences · NCT06497985
- Jan 8, 2029Primary completion: phase 3 study in Endometrial NeoplasmsHUTCHMED · NCT06584032
- Sep 30, 2029Primary completion: phase 2 study in Carcinoma, HepatocellularCSPC Pharmaceutical Group · NCT07761286
TargetBeta
“A recombinant human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1; PDCD1; PD1), ”NCIt, by rule
“Programmed cell death protein 1 antagonist”ChEMBL 37, by rule
Other programs on PDCD1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivonescimabrule | Akeso | phase 3 | 48 |
| rilvegostomig | AstraZeneca | phase 3 | 24 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| tivunatamig | Pfizer | phase 3 | 15 |
| nilvanstomigrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 15 |
| pucotenlimabrule | taizhou-hanzhong-biomedical-co-ltd | phase 3 | 15 |
| enlonstobartrule | CSPC Pharmaceutical Group | phase 3 | 15 |
| ezabenlimab | Boehringer Ingelheim | phase 3 | 13 |
| Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363rule | Innovent Biologics | phase 3 | 10 |
| rulonilimabrule | Lunan Pharmaceutical Group | phase 3 | 9 |
| Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 | Sino Biopharmaceutical | phase 3 | 4 |
Studies
All 40 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07917468Locally Advanced Rectal Cancer · China | 3 | Not yet recruiting | Innovent Biologics | Mar 25, 2030 | 500 |
| NCT07761286Carcinoma, Hepatocellular · China | 2 | Not yet recruiting | CSPC Pharmaceutical Group | Sep 30, 2029 | 288 |
| NCT07643623Resectable Gastric/Gastroesophageal Junction Adenocarcinoma · China | 3 | Recruiting | Innovent Biologics | Dec 31, 2031 | 720 |
| NCT07521852Carcinoma, Hepatocellular · China | 2 | Recruiting | TaiRx | Dec 31, 2027 | 40 |
| NCT07483567CLDN18.2 Positive · China | 2 | Recruiting | Innovent Biologics | Jun 30, 2030 | 90 |
| NCT07005336Carcinoma, Non-Small-Cell Lung · China | 2 | Active, not recruiting | TJ Biopharma | Aug 30, 2026 | 150 |
| NCT06773312Stomach Neoplasms · China | 1 | Recruiting | Sichuan Luzhou Buchang Biopharmaceutical | Oct 2026 | 80 |
| NCT06584032Endometrial Neoplasms · China | 3 | Recruiting | HUTCHMED | Jan 8, 2029 | 412 |
| NCT06558227Carcinoma, Hepatocellular · China | 2 | Recruiting | Suzhou Zelgen Biopharmaceuticals | Sep 2026 | 90 |
| NCT06497985Colorectal Neoplasms · China | 3 | Recruiting | Chipscreen Biosciences | May 31, 2028 | 430 |
| NCT05849246Non-squamous Non-small-cell Lung Cancer · China | 2 | Terminated | Innovent Biologics | Nov 30, 2023 | 4 |
| NCT05718219Advanced Solid Tumors · China | 1 | Terminated | Simcere Pharmaceutical Group | Apr 30, 2025 | 49 |
| NCT05632939Stomach Neoplasms · China | 2 | Active, not recruiting | Beijing Aosaikang Pharmaceutical | Oct 31, 2025 | 62 |
| NCT05572463Melanoma · United States, Australia, France and more | 2 | Withdrawn | Innovent Biologics | Jun 30, 2027 | 0 |
| NCT05522231Advanced Renal Cell Carcinoma · China | 3 | Completed | HUTCHMED | Aug 28, 2026 | 265 |
| NCT05337267Healthy Male Subjects · China | 1 | Completed | Innovent Biologics | May 24, 2023 | 117 |
| NCT05280626Lymphoma, Large B-Cell, Diffuse | 2 | Not yet recruiting | Innovent Biologics | Dec 31, 2025 | 100 |
| NCT05119998Solid Tumor · China | 1 | Completed | Innovent Biologics | Jul 27, 2023 | 48 |
| NCT05116462Carcinoma, Non-Small-Cell Lung · China | 3 | Active, not recruiting | Innovent Biologics | Sep 30, 2026 | 506 |
| NCT05039658DLBCL · China | 1 | UNKNOWN | Innovent Biologics | Jul 12, 2022 | 50 |
| NCT04675983Gastric Adenocarcinoma · China | 3 | Terminated | Innovent Biologics | Feb 12, 2023 | 36 |
| NCT04427774Advanced or Metastatic Solid Tumors · China | 1 | Terminated | Innovent Biologics | Feb 8, 2021 | 8 |
| NCT04401813Advanced Hepatocellular Carcinoma · China | 1 | Completed | Innovent Biologics | Jun 21, 2024 | 97 |
| NCT04353830Advanced Malignancies · China | 1 | Completed | Innovent Biologics | May 11, 2022 | 34 |
| NCT04277663Acral Melanoma That Has Been Removed by Surgery · China | 3 | Terminated | Innovent Biologics | Feb 28, 2023 | 136 |
| NCT04258111Colorectal Neoplasms · China | 2 | Terminated | Innovent Biologics | Oct 26, 2020 | 4 |
| NCT04177290Carcinoma, Non-Small-Cell Lung · China | 1 | Completed | Innovent Biologics | Feb 28, 2021 | 48 |
| NCT04085185Advanced Malignancies · China | 1 | UNKNOWN | Innovent Biologics | Dec 15, 2023 | 268 |
| NCT04044222Classic Hodgkin's Lymphoma · China | 3 | UNKNOWN | Innovent Biologics | Jul 30, 2023 | 240 |
| NCT03903705Advanced Solid Tumor · China | 2 | Completed | HUTCHMED | Nov 15, 2023 | 348 |
| NCT03802240Non-Squamous Non-Small Cell Lung Cancer · China | 3 | Completed | Innovent Biologics | Jul 31, 2021 | 492 |
| NCT03745170Stomach Neoplasms · China | 3 | Completed | Innovent Biologics | Jun 20, 2021 | 650 |
| NCT03748134Esophageal Squamous Cell Carcinoma · United States, Australia, Belgium and more | 3 | Completed | Innovent Biologics | Sep 9, 2021 | 746 |
| NCT03629925Squamous NSCLC · China | 3 | Completed | Innovent Biologics | Mar 25, 2020 | 357 |
| NCT03607539Lung Neoplasms · China | 3 | Completed | Innovent Biologics | Nov 15, 2019 | 397 |
| NCT03568539Advanced/Metastatic Solid Malignancies · United States | 1 | Completed | Innovent Biologics | Nov 9, 2020 | 39 |
| NCT03228836Effect of Drugs · China | 2 | Completed | Innovent Biologics | Feb 28, 2020 | 28 |
| NCT03150875Carcinoma, Non-Small-Cell Lung · China | 3 | Completed | Innovent Biologics | Feb 22, 2023 | 290 |
| NCT03116152Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Innovent Biologics | Oct 2, 2019 | 190 |
| NCT02937116Neoplasms · China | 1 | Completed | Innovent Biologics | Sep 30, 2020 | 233 |
How it is read
Names in the registry
- “Sintilimab”, 15 entries
- “IBI308”, 5 entries
- “IBI939+ Sintilimab”, 2 entries
- “IBI110+ Sintilimab”, 2 entries
- “fruquintinib+sintilimab”, 1 entry
Codes read as this program: IBI308.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Hepatocellular, 4 studies
- Stomach Neoplasms, 3 studies
- Colorectal Neoplasms, 2 studies
- Esophageal Squamous Cell Carcinoma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.